What is Xenon Pharmaceuticals's EBITDA margin?

Xenon Pharmaceuticals (XENE) reported EBITDA margin of -4,940.4% in Q4 2025.

What is the long-term trend for Xenon Pharmaceuticals's EBITDA margin?

Over 3 years (2020 to 2025), Xenon Pharmaceuticals's EBITDA margin has grown at a 272.9% compound annual growth rate (CAGR), from -95.3% to -4,940.4%.

What does EBITDA margin mean?

EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.

Xenon Pharmaceuticals XENE EBITDA margin

EBITDA margin at other companies

Eli LillyLLY

45.9%+14.4pp

Johnson & JohnsonJNJ

34.4%+2.7pp

Jazz PharmaceuticalsJAZZ

-10.9%-28.0pp

Axsome TherapeuticsAXSM

-23.5%-8.9pp

Praxis Precision Medicines, Inc.PRAX

-3,925.4%-1,495pp

Neurocrine BiosciencesNBIX

26.4%+4.7pp

Other financials

Income statement

See full

Revenue--100%

Operating income-$112.3M-54.4%

Net income-$102.3M-57.3%

EPS (diluted)-$1.17-41.0%

Balance sheet

See full

Cash & equivalents$545.9M+368%

Total debt$7.5M-13.6%

Total equity$1.3B+90.0%

Total assets$1.4B+86.6%

Cash flow

See full

Operating cash flow-$88.9M-44.2%

CapEx$133.0K+209%

Free cash flow-$89.0M-44.3%

Valuation

See full

Market cap$5.11B+116%

Profitability

See full

Operating margin-4,974.3%—

Net margin-4,612.1%—

FCF margin-3,732.2%—

Returns & leverage

See full

Return on equity-37.5%+8.7pp

Debt / equity0×0.0×

Current ratio27.8×+10.1×

Where this comes from

Calculated from Xenon Pharmaceuticals’s reported figures.

ebitda/total revenue=-4,940.4%

Based on trailing twelve months.

The official record: Xenon Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Xenon Pharmaceuticals's ebitda margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Xenon Pharmaceuticals's EBITDA margin?: Xenon Pharmaceuticals (XENE) reported EBITDA margin of -4,940.4% in Q4 2025.
What is the long-term trend for Xenon Pharmaceuticals's EBITDA margin?: Over 3 years (2020 to 2025), Xenon Pharmaceuticals's EBITDA margin has grown at a 272.9% compound annual growth rate (CAGR), from -95.3% to -4,940.4%.
What does EBITDA margin mean?: EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.